New hope for rare blood disorder treatment in africa
NCT ID NCT04585893
Summary
This study is testing whether the drug rituximab is safe and effective for treating multicentric Castleman disease in Malawi. The trial involves 15 adults with active disease who receive four weekly doses of rituximab, with some higher-risk patients also receiving chemotherapy. Researchers will monitor patients for two years to check safety, survival rates, and whether symptoms improve.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTICENTRIC CASTLEMAN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Project, Kamuzu Central Hospital
Lilongwe, Malawi
Conditions
Explore the condition pages connected to this study.